1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Baseline and follow-up
Preoperative Mean±SD (range)Postoperative Mean±SD (range)P
Sex (M/F)73/6573/65–
Age (years)62.08 ± 8.52 (35–82)62.08 ± 8.52 (35–82)–
Durations (years)11.72 ± 4.73 (5–29)11.72 ± 4.73 (5–29)–
LEDD (mg)773.37 ± 351.27 (0–1735.65)555.66 ± 291.21 (0–1580)<.001
MDS-UPDRS-III (med off)49.86 ± 16.00 (18–97)24.61 ± 13.49 (3–65)<.001
MDS-UPDRS-III-tremor (med off)10.95 ± 7.68 (0–33)3.33 ± 4.35 (0–22)<.001
MDS-UPDRS-III-rigidity (med off)8.78 ± 3.67 (2–23)2.75 ± 2.92 (0–12)<.001
FOGQ11.58 ± 8.22 (0–24)7.54 ± 7.47 (0–24)<.001
Berg37.62 ± 13.36 (1–56)45.84 ± 10.21 (2–56)<.001
MoCA21.82 ± 4.22 (10–30)21.90 ± 4.39 (10–30).564
HAMA18.41 ± 9.53 (2–51)12.31 ± 8.57 (0–44)<.001
HAMD18.25 ± 9.18 (1–58)13.85 ± 10.15 (0–55)<.001
  • Note:—Outcome changes from baseline to follow-up of each group were tested by using Wilcoxon signed-rank tests. LEDD indicates levodopa equivalent dose.